ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021
Combined Inhibition of Gα
Open access · bronzeAbstract readComment
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 46 citations in OpenAlex.
- RAB1A is a novel vulnerability in uveal melanoma revealed by dual inhibition of MNK1/2 and mTOR.Cell death and differentiation · 2026Article
- Does the ERBB/EGF Signaling Network Serve as a Nexus for Oncogenic Signals in Uveal Melanoma?Biomolecules · 2026Review
- Vascular malformations: from genetics to therapeutics.EMBO molecular medicine · 2026Review
- Conserved Gαq-PLCβ-PKC signaling mediates trametinib resistance in BRAFbioRxiv : the preprint server for biology · 2025Article
- Allele-specific depletion ofMolecular therapy. Oncology · 2025Article
- Neuropeptide Precursor VGF Promotes Liver Metastatic Colonization of Gαq Mutant Uveal Melanoma by Facilitating Tumor Microenvironment via Paracrine Loops.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Genetic Features of Uveal Melanoma.Genes · 2024Review
- Going Rogue: Mechanisms, Regulation, and Roles of Mutationally Activated GMolecular pharmacology · 2024Review
- The role of signaling pathways mediated by the GPCRs CysLTR1/2 in melanocyte proliferation and senescence.Science signaling · 2024Review
- Article
- Review
- Extracellular Matrix Cues Regulate Mechanosensing and Mechanotransduction of Cancer Cells.Cells · 2024Review
- Beyond matrix stiffness: targeting force-induced cancer drug resistance.Trends in cancer · 2023Review
- IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression.Molecular cancer therapeutics · 2023Article
- Thiol-Disulfide Exchange Coordinates the Release of Nitric Oxide and Dexamethasone for Synergistic Regulation of Intestinal Microenvironment in Colitis.Research (Washington, D.C.) · 2023Article
- Darovasertib, a novel treatment for metastatic uveal melanoma.Frontiers in pharmacology · 2023Review
- Exploring pharmacological inhibition of GBritish journal of pharmacology · 2022Article
- The future of targeted kinase inhibitors in melanoma.Pharmacology & therapeutics · 2022Review
- Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling.Cancer gene therapy · 2022Article
- Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics.The Journal of investigative dermatology · 2022Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
18 authors at 3 institutions in 3 countries.
Tyler D HitchmanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Gabriella Bayshtok *Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Emilie Ceraudo *Laboratory of Chemical Biology and Signal Transduction, The Rockefeller University, New York, New York.ORCID 0000-0001-6563-9751
Amanda R MooreHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-3864-6387
Cindy LeeHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Ruobing JiaHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Naitao WangHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Mohini R PachaiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Alexander N ShoushtariDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-8065-4412
Jasmine H FrancisOpthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-7637-3108
Youxin GuanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Juliet ChenHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-0171-3884
Matthew T ChangHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Barry S TaylorHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Thomas P SakmarLaboratory of Chemical Biology and Signal Transduction, The Rockefeller University, New York, New York.ORCID 0000-0002-2836-8953
Thomas HuberLaboratory of Chemical Biology and Signal Transduction, The Rockefeller University, New York, New York.
Ping ChiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. cheny1@mskcc.org chip@mskcc.org.
Yu ChenHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. cheny1@mskcc.org chip@mskcc.org.ORCID 0000-0002-0171-3884
Memorial Sloan Kettering Cancer Center · USRockefeller University · USKarolinska Institutet · SE
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MSPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI JAMES A EASTHAM · 2001 to 2026
$63.0MSPORE in Soft Tissue SarcomaP50CA140146 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LADANYI, MARC · 2010 to 2014
$11.1MRole of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceR01CA193837 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2015 to 2025
$4.7MAn integrative approach to target lineage-specific oncogenic transcription factorDP2CA174499 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHI, PING · 2012 to 2012
$2.6MEpigenetic mechanisms of transcriptional activation of a novel oncogenic ALK variant in cancerR01CA228216 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHI, PING · 2018 to 2022
$2.5MUnderstanding the role of an aberrant hepatic nuclear transcription circuit in prostate cancer tumorigenesis and castration resistanceR01CA208100 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHEN, YU · 2017 to 2021
$2.5MDefining the impact of mutant oncogene zygosityR01CA245069 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHANDARLAPATY, SARAT · 2020 to 2024
$2.0MUnderstanding Long Tail Driver Mutations in CancerR01CA204749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCHULTZ, NIKOLAUS · 2017 to 2021
$2.0MElucidating the roles of ETV1 in the pathogenesis of GISTK08CA151660 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHI, PING · 2011 to 2015
$848kUnderstanding the roles of TMPRSS2 and ERG in pathogenesis of prostate cancer.K08CA140946 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHEN, YU · 2009 to 2013
$796kNCI NIH HHS DP2 CA174499NCI NIH HHS F31 CA236030NCI NIH HHS K08 CA140946NCI NIH HHS K08 CA151660NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS P50 CA140146NCI NIH HHS R01 CA193837NCI NIH HHS R01 CA204749NCI NIH HHS R01 CA208100NCI NIH HHS R01 CA228216NCI NIH HHS R01 CA245069
Abstract
purposeAll uveal melanoma and a fraction of other melanoma subtypes are driven by activation of the G-protein alpha-q (Gα EXPERIMENTAL
designWe used an isogenic melanocytic cellular system to systematically examine hotspot mutations in
resultsWe demonstrate that the Gα
conclusionsThese data suggest that the combination of Gα
Indexed as
MelanomaUveal NeoplasmsCell Line, TumorGTP-Binding Protein alpha SubunitsGTP-Binding Protein alpha Subunits, Gq-G11HumansMitogen-Activated Protein Kinase KinasesMutationUveal MelanomaGTP-Binding Protein alpha SubunitsGTP-Binding Protein alpha Subunits, Gq-G11Mitogen-Activated Protein Kinase Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.